메사추세츠 비즈니스 컨퍼런스

메사추세츠 비즈니스 컨퍼런스에서 패널 디스커션에 참여했습니다. 보스턴 상공회의소 회장님과 함께 경제 전망에 대해 이야기를 나눌 수 있었던 뜻깊은 시간이었습니다. 디스커션에서 제가 이야기했던 내용입니다. 초대해주셔서 다시 한번 감사드립니다.

1. Most important factor in investment decision

The most important factor is the team. In biotech, teams must be able to pivot their plans when facing challenges. What I evaluate is how effectively they can resolve issues when they inevitably arise.

In terms of exciting markets, AI presents tremendous opportunities. Consider how obesity treatments like GLP-1s were major drivers in 2023-2024, propelling Lilly and Novo Nordisk to $1 trillion valuations. Yet Nvidia reached $4 trillion primarily due to AI. This raises an intriguing question: what might valuations look like when AI is effectively applied to healthcare and life sciences? The potential for value creation is substantial.

2. Bio startup investment trends and outlook

Taking a step back, if we recall ten years ago, 2013-2014 represented a golden era for biotech. CRISPR and gene editing technologies emerged, and valuations skyrocketed. This was followed by a correction period in 2015. After recovery between 2016-2017, the market surged again during COVID.

This boom-burst-recovery cycle is natural in our industry. I believe 2025 will be a year of recovery – or as some call it, a reset. Investors are becoming more selective, prioritizing capital-efficient, clinically validated assets, with sectors like AI-driven drug discovery and obesity treatments attracting the most attention.

3. Effects of interest rate cuts

Of course, rate cuts are helpful since money is becoming cheaper. HSBC reported that in Q4 2024, VC funding increased by approximately 5% due to interest rate cuts and eased financial pressure.

In fact, interest rates are not a valid excuse for lack of investment in transformative technologies. Consider the early 1980s – a period of stagflation with the Federal Reserve’s aggressive tightening under Paul Volcker. The federal funds rate peaked at 20% in June 1981, inflation hovered near 14%, and unemployment exceeded 10%. Conventional wisdom suggested biotech firms would collapse under such conditions.

Yet during this hostile environment, Genentech’s 1980 IPO marked biotechnology’s arrival as an investable sector. The offering raised $35 million, with shares skyrocketing 150% on their first trading day, valuing the company at $532 million. This “biomania” emerged despite record-high interest rates because investors recognized transformative potential.

Investment decisions are ultimately psychological processes, and restoring confidence is perhaps more important than the rate environment. We expect IPOs to return gradually in 2025, while late-stage funding remains the primary focus for VCs.

4. Potential variables affecting the outlook

Risks:

• Regulatory uncertainty: The Inflation Reduction Act pricing policies are affecting long-term pharma revenue models, and the FDA’s evolving stance on accelerated approvals adds unpredictability
• M&A and market volatility: Q4 2024 saw only 18 biopharma M&A transactions, the lowest since early 2022
• Investors favoring later-stage deals with strong clinical data over early-stage speculative investments
• Geopolitical risks and supply chain challenges: The BIOSECURE Act increases scrutiny on foreign biotech firms, particularly from China

Opportunities:

• Leadership changes at HHS could shift focus toward preventive healthcare
• Medical food and chronic disease prevention align with Korean expertise in functional foods and medical nutrition products
• Microbiome innovations: Korea leads in gut health research, positioning it well for microbiome-based therapies and diagnostics
• Interest rate cuts beginning to unlock capital, potentially accelerating M&A activity in 2025 as lower borrowing costs make acquisitions more attractive

5. Creating synergy with Boston’s bioecosystem

Korean companies can create synergy with Boston’s bioecosystem by:

• Leveraging the complementary strengths between Seoul and Boston as highlighted in the presentation – Boston has strong R&D capabilities (14.9% of US pipeline and 6.5% of global pipeline) and robust venture funding (32% of US Bio/Healthcare VC funding), while Seoul offers excellent clinical trial infrastructure (global leading clinical trial city for seven consecutive years) and strong manufacturing capabilities (86,000 hospital beds vs 4,000 in Boston/Cambridge)
• Establishing strategic partnerships with Boston’s academic institutions and research hospitals, which are among the world’s leading biomedical research centers
• Focusing on areas where Korean strengths align with Boston needs, such as microbiome research, functional foods, and AI-driven biotech
• Understanding that Boston remains the #1 hub for cross-border biotech licensing, making it an ideal location for collaboration
• Building credibility through local presence – companies with Boston-based operations attract more funding and partnership opportunities
• Recognizing that Big Pharma in Boston prioritizes later-stage assets – licensing payments are highest for Phase II and Phase III deals, which aligns with Korean companies’ development strengths

6. Advice for Korean biotech companies

Korean biotechs entering Boston must:

• Align with investor expectations by having strong clinical data, regulatory clarity, and a clear commercialization path
• Focus on areas of strength like microbiome-based therapies, medical nutrition, and AI-powered biotech that align well with U.S. healthcare trends

I’d like to highlight two instructive case studies:

1. Celltrion’s Avalanche Pharmaceuticals acquisition: This $2.7 billion acquisition strengthens Celltrion’s U.S. production capabilities, increasing domestic manufacturing from 35% to 70% by 2026 through Avalanche’s Arizona GMP facility. The deal’s dual domicile structure enables operational flexibility and mitigates risks from potential U.S. tariff policy changes.

2. WuXi Biologics’ Worcester facility: WuXi is investing $300 million in a 189,500-square-foot biomanufacturing facility at The Reactory biotech park in Worcester, Massachusetts. This project will create 200 jobs and enhance local manufacturing capacity by 2025. However, the BIOSECURE Act, targeting Chinese biotech firms over national security concerns, has introduced uncertainty regarding the facility’s future. Despite this, Congressman Jim McGovern has opposed the bill, citing lack of transparency and due process.

These cases underscore several critical strategies for Korean biotechs:

• Establish local manufacturing or R&D facilities to enhance credibility and access to U.S. markets
• Proactively address regulatory and geopolitical concerns through transparency, partnerships, and innovative deal structures
• Leverage strategic acquisitions to accelerate market entry and strengthen position
• Create economic impact through job creation and infrastructure development to build local goodwill
• Adopt flexible corporate structures to mitigate political and regulatory risks
• Understand that having a Boston-based presence significantly increases funding opportunities

The WuXi Biologics case particularly highlights how geopolitical dynamics can influence biotech investments. Korean companies entering the U.S. market should prioritize building local infrastructure while aligning with regulatory expectations to ensure long-term success.

Celltrion’s approach demonstrates that proactive strategies—enhancing local production capacity and mitigating geopolitical risks through innovative deal structures—can create sustainable growth opportunities in the U.S. market.

7. Why early stage companies are struggled?

I believe investor confidence is a more important factor. We need to consider why investors have been hesitant to fund new companies:

• Clinical development costs have doubled to $2.3 billion over the decade
• It takes 50% more time to enroll patients in clinical trials
• Revenue expectations are lower due to policies like the Inflation Reduction Act